Status:
UNKNOWN
Phase IV Clinical Trial of Nimotuzumab in the Treatment of Nasopharyngeal Carcinoma
Lead Sponsor:
Biotech Pharmaceutical Co., Ltd.
Conditions:
Nasopharyngeal Carcinoma
Eligibility:
All Genders
Phase:
PHASE4
Brief Summary
This clinical study is designed as an open, single group, multi-center, phase 4 clinical study to assess the safety of Nimotuzumab in the treatment of nasopharyngeal carcinoma and to provide a more re...
Detailed Description
This clinical study is designed as an open, single group, multi-center, phase 4 clinical study to assess the safety of Nimotuzumab in the treatment of nasopharyngeal carcinoma and to provide a more re...
Eligibility Criteria
Inclusion
- Patients with histologically or cytologically confirmed nasopharyngeal carcinoma
- Sex and age without limiting
- Treatment without limiting
- Subjects with reproductive potential (males and females) willing to use reliable means of contraception
- Able and willing to give written informed consent and comply with the requirements of the study protocol
Exclusion
- Patients with severe allergies or idiosyncratic constitution
- Women who are pregnant (determined by urine pregnancy test)or breast feeding
- Any other severe complications or functional disorder of organ systems, which will affect the evaluation of safety of patients or will interfere with the test drug according to the researcher's point of view
Key Trial Info
Start Date :
August 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
2000 Patients enrolled
Trial Details
Trial ID
NCT02293356
Start Date
August 1 2015
End Date
December 1 2017
Last Update
August 19 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cancer Institute & Hospital.Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021